Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021. “Bellerophon remains focused on advancing its INOpulse® inhaled nitric oxide therapy in multiple high-value areas of unmet need as expeditiously a...